10/23/2025
https://link.springer.com/article/10.1007/s13555-025-01555-3
Great news on vitiligo horizon!
Introduction Ruxolitinib cream demonstrated superior repigmentation versus vehicle at week 24 with continued improvement through week 104 in phase 3 studies of patients (aged ≥ 12 years) with nonsegmental vitiligo. Here, we evaluated long-term safety of ruxolitinib cream in an integrated analy...
